AlphAIalphai — Financial news for AI agents
fnarena.comMAY 256 min read$ALCBullishMed

Australian Broker Call *Extra* Edition

FNArena launched “The Australian Broker Call Extra Edition,” which adds additional broker research coverage but is updated “regularly” rather than daily, so post-publication information may lag. The issue summarizes broker views on ASX stocks including AFT Pharmaceuticals (Jarden Overweight; target NZ$4.25) and Alligator Energy (Argonaut Speculative Buy; $0.07 target), plus Alcidion Group (Canaccord Buy; $0.14 target) and Moelis Buy ($0.16).

AI DeskMay 25, 2026
Source · fnarena.com
AI analysis
Relevance
9/10
Actionability
Med
Sentiment · $ALC
Bullish
Timing
Morning/early-session relevance for ASX small/mid caps as broker targets and initiations can drive same-day positioning.
Market alignment
Generally bullish across the covered names (Overweight/Buy/Speculative Buy) with clear catalysts (FY results, acquisition, de-risking trial).
Why this matters for $ALC

M&A bolt-on with recurring revenue and customer adds is a direct earnings driver for ALC, supporting positive sentiment.

Relevance context

Canaccord maintained a Buy on Alcidion Group after it acquired Telstra Health’s Kyra Flow suite, lifting FY27–FY28 projections 14–15%.

Price-impact prediction

Near-term upside bias as investors focus on integration, recurring revenue ramp, and the raised forecast trajectory.

Background

This is an FNArena “Broker Call Extra Edition” compiling broker recommendations/valuation changes for multiple ASX-listed stocks; it is not a primary newswire but a curated research summary.

Why it matters

Trading impact comes from broker rating/target changes and from concrete company-specific catalysts mentioned (FY results, acquisition economics, uranium trial de-risking).

Market relevance

The actionable items are three company-specific broker updates: AFT target increase post-FY26 beat, AGE coverage initiation after technical de-risking, and ALC Buy/forecast uplift after a bolt-on acquisition.

Market effects

Sector

Broker activity highlights continued investor appetite for healthcare services roll-ups (ALC) and de-risking milestones in uranium development (AGE).

Regional

Primarily impacts Australian-listed small/mid-cap sentiment via broker target changes and coverage initiation updates.

Global

Limited direct global spillover; however, uranium-specific optimism can marginally influence broader nuclear fuel sentiment.

Alternative perspectives

Contrarian view

Broker-note summaries can overstate near-term certainty; integration execution (ALC) and feasibility/licensing timelines (AGE) may slip.

Overlooked factors

Cash flow and net debt sensitivity (AFT) and contract finalization timing (ALC’s UH Sussex target for May) could temper follow-through despite upgrades.

Key entities

  • publisher
    FNArena

    Curates broker research and updates for ASX-listed equities; notes may not be fully up to date after publication.

  • broker
    Jarden

    Raised its target for AFT Pharmaceuticals after FY26 results and FY27 guidance.

  • broker
    Argonaut

    Initiated coverage on Alligator Energy with a Speculative Buy and a $0.07 target.

  • broker
    Canaccord Genuity

    Maintained a Buy on Alcidion Group following the Kyra Flow acquisition from Telstra Health.

Read at source← All news

Related articles

JUN 4
$NVSLow

Swiss Market Ends On Strong Note

Swiss stocks ended higher on Thursday after a cautious start. The SMI rose 0.93% to close at 13,341.27 (intraday high 13,395.00). Roche gained 4.2% after developing a research-use-only PCR test for the rare Ebola Bundibugyo virus. Partners Group rose 3.73%; Novartis, Alcon, Sonova and SGS gained 1.6%-2%. Switzerland’s unemployment rate held at 3% in May, SECO said.

finanznachrichten.de4 min
JUN 2
$LOGILow

Swiss Market Fails To Hold Gains, Ends Flat

Swiss shares ended flat on Tuesday as gains faded while investors weighed differing accounts of Middle East talks between U.S. President Donald Trump and Israeli PM Benjamin Netanyahu. The SMI finished at 13,305.72 versus 13,305.40. VAT Group (+5%), Logitech (+3.7%) and ABB (+3.21%) rose; Roche and Swiss Re fell 1.4%-2.5%. Switzerland’s trade surplus widened to CHF 3.2bn in April.

finanznachrichten.de4 min
MAY 28
$ALCMed

Swiss Market Ends Notably Lower

Swiss stocks fell on Thursday as investors stayed cautious amid Middle East tension worries. The SMI ended down 122.65 points (0.9%) at 13,504.76 after opening weak and trading in negative territory. Losers included Partners Group, Swiss Life, Julius Baer, Zurich and Sonova (-2% to -2.5%). Kuehne+Nagel and Lonza rose (+1% to +1.5%). Switzerland non-farm payrolls rose 0.5% y/y to 5.537 million in Q1 2026, per the Federal Statistical Office.

finanznachrichten.de3 min
APR 20
$ALCMed

Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside?

Alcon Inc. (CH0432492467) offers investors defensive exposure to the eye care sector through its global leadership in surgical devices, contact lenses, and pharmaceuticals. The company's dual business model, focusing on both Surgical and Vision Care, along with significant R&D investment, provides stable cash flows and pricing power. This positions Alcon for steady growth driven by an aging global population and rising vision needs, making it a resilient option for long-term portfolios despite potential risks like reimbursement cuts and supply chain disruptions.

AD HOC NEWS3 min
MAR 26
$ALCMed

Systane Eye Drops: Alcon's Leading Solution for Dry Eye Relief in North America

Systane eye drops, produced by Alcon, offer fast and long-lasting relief for dry and irritated eyes, a common issue in North America exacerbated by screen time and environmental factors. The product utilizes a unique gel-forming technology for extended hydration and is a significant part of Alcon's consumer health portfolio. Its strong market position and brand loyalty contribute to Alcon's stable revenue and shareholder value, appealing to investors in the resilient eye care sector.

AD HOC NEWS2 min